|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
MARKET FACILITATION INDEX
Trading: SELL @ $1.805
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Mesoblast (ASX:MSB) Currently is a confirmed Fake Day.
The Market Facilitation Index is designed for evaluation the willingness of the market to move the price. The indicators absolute values alone cannot provide any trading signals unlike its dynamics in relation to the dynamics of the volume.
Calculation: Bill Williams Market Facilitation Index:
1) Green bar - both MFI and volume are up. Increasing trading activity means market movement acceleration;
2) Blue bar - MFI indicator is up volume is down. The movement is continuing although the volume has dropped. The trend will soon be reversing;
3) Pink bar - MFI indicator is down volume is up. The slowing down movement while volume is raising may indicate a possible break through often a U-turn;
4) Brown bar - both MFI and volume are down. The market is no longer interested in the current direction and is looking for signs of a future development;
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|SMN Structural Monitoring Systems||0.98||4.8||47,285||0||NEUTRAL|
|KAR Karoon Gas Australia||1.1||3.8||5,014,070||0||NEUTRAL|
|PME Pro Medicus||26.36||3||303,033||0||NEUTRAL|